Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Determinants of Gestational Weight Gain in Obese Pregnant Women (MomEE)

23. august 2021 oppdatert av: Leanne Redman, Pennington Biomedical Research Center

MomEE: Determinants of Gestational Weight Gain in Obese Pregnant Women

The purpose of this study is to measure energy intake and energy expenditure during and after pregnancy. The investigators hypothesize that obese pregnant women with weight gain above the Institute of Medicine (IOM) guidelines, 'High Gainers', will have increased energy intake but no evidence for changes in energy expenditure after adjustment for the weight gained when compared to women with appropriate gestational weight gain, 'Normal Gainers'. Additionally, the investigators will measure the babies born to the pregnant women enrolled in MomEE at one time point before 10 days of life.

Studieoversikt

Status

Fullført

Studietype

Observasjonsmessig

Registrering (Faktiske)

72

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Louisiana
      • Baton Rouge, Louisiana, Forente stater, 70808
        • Pennington Biomedical Research Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 40 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Hunn

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

75 obese, pregnant women

Beskrivelse

Inclusion Criteria:

  • Are pregnant
  • Have a body mass index (BMI) greater than or equal to 30kg/m2
  • Are 18-40 years old
  • Medically cleared for participation by primary care obstetrician
  • Medically cleared for participant by Medical Investigator
  • Willingness to allow the study access to information in the participant's medical record
  • Willingness to be notified of incidental findings from study procedures

Exclusion Criteria:

Clinical

  • Hypertension (i.e. systolic blood pressure (SBP) >160 mmHg & diastolic blood pressure (DBP) >110 mmHg)*
  • Diagnosis of diabetes prior to pregnancy
  • Hb A1c ≥6.5 %*
  • Implanted metal objects that render MRI unsafe
  • HIV or AIDS (self-reported)
  • Severe anemia (hemoglobin <8g/dL and/or hematocrit <24%)** Psychological
  • History or current psychotic disorder or diagnosis of a current major depressive episode or bipolar disorder
  • Past history of anorexia or bulimia by medical history or patient report (binge eating disorder is not an exclusion) or current eating disorder
  • Actively suicidal defined as a value ≥2 on the Beck Depression Index (BDI-II) question 9* Medications
  • Current use of one or more of the following medications: metformin, systemic steroids, antipsychotic agents (e.g., Abilify, Haldol, Risperdal, Seroquel, Zyprexa), anti-seizure medications or mood stabilizers that would be expected to have a significant impact on body weight (e.g., Depakote, Lamictal, Lithium, Neurontin, Tegretol, Topamax, Keppra), medications for attention-deficit/hyperactivity disorder (ADHD) including amphetamines and methylphenidate
  • Continued use of weight loss medication including over the counter (OTC) and dietary supplements for weight loss (e.g., Adipex, Suprenza, Tenuate, Xenical, Alli, conjugated linoleic acid, Hoodia, Green tea extract, Guar gum, HydroxyCut, Sensa, Corti-slim, Chromium, chitosan, Bitter orange) Other Exclusion Criteria
  • Recent history of or currently smoking, drinking alcohol or abusing drugs (prescription or recreational)
  • Plans to move out of the study area within the next 2 years or plans to be out of the study area for more than 4 weeks in the next 12 months
  • Planned termination of pregnancy
  • Unwillingness to avoid pregnancy for 12 months following delivery
  • Claustrophobia
  • Prior or planned (within 1 year of expected delivery) bariatric surgery
  • Participant's unwillingness or inability to commit to a 1 year follow-up

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Pregnant
Obese pregnant women

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Energy Intake
Tidsramme: Approximately 6 months (from 13-16 weeks gestation to 35-37 weeks gestation)
Energy intake is determined using the energy intake-balance method. Energy intake was calculated as the sum of energy expenditure by doubly labeled water and energy deposition of fat and fat-free tissues by 3 compartment model using plethysmography and isotope dilution.
Approximately 6 months (from 13-16 weeks gestation to 35-37 weeks gestation)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Physical Activity
Tidsramme: Approximately 7 days within 13-16 weeks gestation
Physical activity is determined using daily mean amplitude deviation in milligrams by wrist worn accelerometer over a period of approximately 7 days within early pregnancy (13-16 weeks gestation). Mean amplitude deviation describes the mean distance of data points from the mean, and higher values denote higher levels of physical activity.
Approximately 7 days within 13-16 weeks gestation
Physical Activity
Tidsramme: Approximately 7 days within 35-37 weeks gestation
Physical activity is determined using daily mean amplitude deviation in milligrams by wrist worn accelerometer over a period of approximately 7 days within late pregnancy (35-37 weeks gestation). Mean amplitude deviation describes the mean distance of data points from the mean, and higher values denote higher levels of physical activity.
Approximately 7 days within 35-37 weeks gestation
Energy Expenditure During Sleep
Tidsramme: 1 day within 13-16 weeks gestation
Energy expenditure during sleep is determined by 1 overnight stay in a whole body calorimeter within early pregnancy (13-16 weeks gestation).
1 day within 13-16 weeks gestation
Energy Expenditure During Sleep
Tidsramme: 1 day within 35-37 weeks gestation
Energy expenditure during sleep is determined by 1 overnight stay in a whole body calorimeter within late pregnancy (35-37 weeks gestation).
1 day within 35-37 weeks gestation
Percentage of Protein of Energy Intake
Tidsramme: Approximately 7 days within 13-16 weeks gestation
Percentage of protein of energy intake is determined by remote food photography method within early pregnancy (13-16 weeks gestation).
Approximately 7 days within 13-16 weeks gestation
Percentage of Protein of Energy Intake
Tidsramme: Approximately 7 days within 35-37 weeks gestation
Percentage of protein of energy intake is determined by remote food photography method within late pregnancy (35-37 weeks gestation).
Approximately 7 days within 35-37 weeks gestation
Percentage of Fat of Energy Intake
Tidsramme: Approximately 7 days within 13-16 weeks gestation
Percentage of fat of energy intake is determined by remote food photography method within early pregnancy (13-16 weeks gestation).
Approximately 7 days within 13-16 weeks gestation
Percentage of Fat of Energy Intake
Tidsramme: Approximately 7 days within 35-37 weeks gestation
Percentage of fat of energy intake is determined by remote food photography method within late pregnancy (35-37 weeks gestation).
Approximately 7 days within 35-37 weeks gestation
Percentage of Carbohydrate of Energy Intake
Tidsramme: Approximately 7 days within 13-16 weeks gestation
Percentage of carbohydrate of energy intake is determined by remote food photography method within early pregnancy (13-16 weeks gestation).
Approximately 7 days within 13-16 weeks gestation
Percentage of Carbohydrate of Energy Intake
Tidsramme: Approximately 7 days within 35-37 weeks gestation
Percentage of carbohydrate of energy intake is determined by remote food photography method within late pregnancy (35-37 weeks gestation).
Approximately 7 days within 35-37 weeks gestation

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Leanne M Redman, PhD, Pennington Biomedical Research

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. desember 2014

Primær fullføring (Faktiske)

1. juli 2017

Studiet fullført (Faktiske)

1. august 2018

Datoer for studieregistrering

Først innsendt

26. september 2013

Først innsendt som oppfylte QC-kriteriene

26. september 2013

Først lagt ut (Anslag)

1. oktober 2013

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. september 2021

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. august 2021

Sist bekreftet

1. august 2021

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • PBRC 13020
  • 1R01DK099175 (U.S. NIH-stipend/kontrakt)

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere